Artiva Biotherapeutics
4747 Executive Drive
Suite 1150
San Diego
California
92121
United States
9 articles with Artiva Biotherapeutics
-
Artiva Biotherapeutics Appoints Two New Independent Members to Its Board of Directors
5/19/2021
Artiva Biotherapeutics appoints Elizabeth L. Hougen, EVP and CFO of Ionis Pharmaceuticals, Inc., has extensive experience in finance and business for public life sciences companies Linda M. Kozick, who led the immuno-oncology product and portfolio strategy for BMS, including Opdivo ® and Yervoy ® , has deep expertise in strategic commercial drug development
-
Artiva Biotherapeutics Appoints Michael E. Faerm as Chief Financial Officer
4/6/2021
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Michael E. Faerm as Chief Financial Officer.
-
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
2/26/2021
Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing.
-
Funds will be used to support the development of its lead asset, AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers.
-
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
1/28/2021
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an exclusive worldwide collaboration and license agreement with Merck, known as MSD outside the United States and Canada, to develop novel chimeric antigen receptor (CAR)-NK cell therapies targeting solid tumor-associated antigens.
-
Today marked some wheeling and dealing in the life sciences industry as several companies licensed products or invested in other companies. Here’s a look.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas
12/7/2020
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today U.S. Food and Drug Administration (FDA) allowance of the company’s investigational new drug (IND) application for AB-101, an optimized and cryopreserved off-the-shelf NK cell therapy.
-
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
6/26/2020
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing allogeneic natural killer cell therapies, announced the launch of the company with the close of a $78 million Series A financing.